Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock prospects.

Over the past several decades, epidemiologic studies have documented declines in sperm count and quality. During the same ...

The NBA Hall of Famer joined forces with the telehealth platform to restart his weight loss journey and raise awareness about ...

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but ...

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...

Mounjaro, initially for type 2 diabetes, gains popularity for weight loss, yet users report severe side effects. Ellie Marie, ...

New data from over 15 million people in Canada shows weight management drugs climbing 90.6 per cent since 2023; diabetes drugs hold top spot; biosimilar adoption up more than 27 per cent.

Shares of Hims & Hers Health (NYSE:HIMS) climbed ~36% in the premarket on Tuesday after the telehealth company announced a ...

New Integration with Gifthealth Simplifies Fulfillment and Medication Visibility for WeightWatchers Clinic MembersNEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW) ...